Volume 21, Issue 1 - Medical Writing in Oncology

The Webscout

Authors: Karin Eichele, Diarmuid De Faoite, Bárbara Wicki

Abstract

Download the full article

References

1. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging 2011;6:243–59.
2. Farquhar-Smith WP. Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 2009;3:7–13.
3. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389–462.
4. Munson A, Harris L, Friedman M, Dewey W, Carchman R. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602.
5. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Δ9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998;436:6–10.
6. Jacobsson S, Wallin T, Fowler C. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 2001;299:951–9.
7. Galve-Roperh I, Sanchez C, Cortes M, del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313–9.
8. Casanova M, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero M, Huffman J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43–50.
9. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova M, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004;64:5617–23.
10. Blazquez C, Casanova M, Planas A, Pulgar TD, Villanueva C, Fernandez-Acenero M, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003;17:529–31.
11. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 2008;100:59–69.
12. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 2010;79:955–66.
13. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DiMarzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 2004;18:1606–8.
14. Petrocellis LD, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998;95:8375–80.
15. Sarker K, Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 2003;60:1200–8.
16. Portella G, Laezza C, Laccetti P, Petrocellis LD, Marzo VD, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003;17:1771–3.
17. Guzman M, Duarte M, Blazquez C, Ravina J, Rosa M, Galve-Roperh I, et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95:197–203.
18. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745–55.
19. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397–411.
20. Bifulco M, DiMarzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547–50.
21. Freimuth N, Ramer R, Hinz B. Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 2010;332:336–44.
22. Leydon GM, Moynihan C, Boulton M, Mossman J, Boudioni M, McPherson K. Cancer patients' information needs and information seeking behaviour: in depth interview study. BMJ 2000;320:909–13.
23. McKenzie J. Similar study had similar findings. Letters to the editor. BMJ 2000;321:632.
24. Hoppe IC. Readability of patient information regarding breast cancer prevention from the Web site of the National Cancer Institute. J Cancer Educ 2010;25(4):490–2.
25. Meredith C, Symonds P, Webster L, Lamont D, Pyper E, Gillis CR, et al. Information needs of cancer patients in west Scotland: cross sectional survey of patients’ views. BMJ 1996;313(7059):724–6.
26. Thomsen OO, Wulff HR, Martin A, Singer PA. What do gastroenterologists in Europe tell cancer patients? Lancet 1993;341(8843):473–6.
27. Evan D. Survey: Israeli doctors withhold information from cancer patients. Haaretz 2011;92(28148):1–2.
28. The NHS Cancer plan: a plan for investment, a plan for reform. Department of Health. 2000 Available from: http://www.cancerinfo.nhs.uk/images/stories/docs/cancer_plan_2000.pdf
29. Mayer DK, Terrin NC, Kreps GL, Menon U, McCance K, Parsons SK, et al. Cancer survivors information seeking behaviors: a comparison of survivors who do and do not seek information about cancer. Patient Educ Couns 2007;65(3):342–50.
30. Hewitt M, Greenfield S, Stovall E, (eds.) From cancer patient to cancer survivor: lost in transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. 2006. Washington D.C., USA: National Academies Press. Available from: http://www.nap.edu/catalog/11468.html.
31. Centers for Disease Control and Prevention (CDC). Cancer survivors—United States, 2007. MMWR. 2011;60(9):269–272.
32. Glaser A. Introduction: a new approach. Health Serv J 2011;2(supplement). Available from: http://www.ncsi.org.uk/wp-content/uploads/HSJ_survivorship_supplement.pdf
33. Wolf SN, Nichols C, Ulman D, et al. Survivorship: an unmet need of the patient with cancer—implications of a survey of the Lance Armstrong Foundation (abstract). J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S), Part I of II (June 1 Supplement): 6032. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=31848.